English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Implantable ventricular assist devices ( VADs ) have proven efficient in advanced heart failure patients as a bridge‐to‐transplant or destination therapy. However,  VAD  usage often leads to infection, bleeding, and thrombosis, side effects attributable to the damage to blood cells and plasma proteins. Measuring hemolysis alone does not provide sufficient information to understand total blood damage, and research exploring the impact of currently available pumps on a wider range of blood cell types and plasma proteins such as  v on  W illebrand factor ( vWF ) is required to further our understanding of safer pump design. The extracorporeal  CentriMag  ( T horatec  C orporation,  P leasanton,  CA ,  USA ) has a hemolysis profile within published standards of normalized index of hemolysis levels of less than 0.01 g/100 L at 100 mm Hg but the effect on leukocytes,  vWF  multimers, and platelets is unknown. Here, the  CentriMag  was tested using bovine blood ( n  = 15) under constant hemodynamic conditions in comparison with a static control for total blood cell counts, hemolysis, leukocyte death,  vWF  multimers, microparticles, platelet activation, and apoptosis. The  CentriMag  decreased the levels of healthy leukocytes ( P  < 0.006), induced leukocyte microparticles ( P  < 10 −5 ), and the level of high molecular weight of  vWF  multimers was significantly reduced in the  CentriMag  ( P  < 10 −5 ) all compared with the static treatment after 6 h in vitro testing. Despite the leukocyte damage, microparticle formation, and cleavage of  vWF  multimers, these results show that the  CentriMag  is a hemocompatible pump which could be used as a standard in blood damage assays to inform the design of new implantable blood pumps.

The C entri M ag Centrifugal Blood Pump as a Benchmark for In Vitro Testing of Hemocompatibility in Implantable Ventricular Assist Devices